Skip to main content
Equibles
RMTG logo

RMTG · Regenerative Medical Technology Group Inc. · Metrics

Track RMTG — free

Use RMTG with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RMTG.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.04 0.00 (-5.76%) At close · Oct 19
Rebalance outlook locked
Going-concern doubt — flagged Aug 19, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since inception, resulting in an accumulated deficit of approximately $79,484,265 and a working capital deficit of $40,328,417 as of June 30, 2026, and future losses are anticipated. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 19, 2026
Market Cap
$548,184
Shares
13.74M
Volume · Oct 19 33.32K Avg daily vol (3M) 76.39K

RMTG metrics

63 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.04
Market cap
$548,184

Price action

20 metrics
Price change (1W)
-20.2%
Price change (30D)
-54.9%
Price change (3M)
-55.2%
Price change (6M)
+59.6%
Price change (YTD)
-18.6%
Price change (1Y)
-27.5%
Trailing year
Price change (5Y)
-53.1%
52-week high
$0.12
52-week low
$0.02
Change from 52-week high
-66.8%
Change from 52-week low
+111.1%
Annualized volatility
330.6%
Annualized volatility (3M)
225.4%
Beta
2.7
RSI (14D)
34.9
Price vs SMA 50
-43.0%
Price vs SMA 200
-24.9%
Avg volume (3M)
87,365
Relative volume
0.0
Average dollar volume
$7,261

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
13.74M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.1×
reciprocal yield 1,717.4%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
2.0
reciprocal yield 49.0%
Earnings yield
-1,713.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
59.8%
Operating margin
0.5%
Trailing 12 months
Net margin
-99.7%
Gross profit (TTM)
$5.63M
Operating profit (TTM)
$43,725
Net income (TTM)
−$9.39M
Trailing 12 months
Diluted EPS (TTM)
$-0.73
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.72
Gross profit per diluted share (TTM)
$0.43
Operating profit per diluted share (TTM)
$0.00
EBITDA per diluted share (TTM)
$0.03
Net income per diluted share (TTM)
$-0.73
Operating cash flow per diluted share (TTM)
$0.02
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-2.74

Growth

11 metrics
Revenue growth YoY
+309.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$9.41M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+5.5%
Year over year · more shares
Revenue CAGR (3Y)
+49.4%
Revenue CAGR (5Y)
+147.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-160.5%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
$406,650
Free cash flow (TTM)
—
Quick ratio
0.0
Interest coverage
0.0
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$1.32M
Total assets
$5.85M
Total debt
$4

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$268,563
Capital expenditures (TTM)
$850,894
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$1.16M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.1%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
26 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1760026 CUSIP 59071L103 Visit website Investor relations